Neuraminidase inhibitors for influenza

Fully evaluating benefits and harms

Andreas Handel, Mark H. Ebell

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish (US)
Pages (from-to)e7-e8
JournalThe Lancet Respiratory Medicine
Volume3
Issue number3
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

Fingerprint

Viral Drug Resistance
Neuraminidase
Human Influenza
Antiviral Agents

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Neuraminidase inhibitors for influenza : Fully evaluating benefits and harms. / Handel, Andreas; Ebell, Mark H.

In: The Lancet Respiratory Medicine, Vol. 3, No. 3, 01.03.2015, p. e7-e8.

Research output: Contribution to journalArticle

Handel, Andreas ; Ebell, Mark H. / Neuraminidase inhibitors for influenza : Fully evaluating benefits and harms. In: The Lancet Respiratory Medicine. 2015 ; Vol. 3, No. 3. pp. e7-e8.
@article{09a5b11e4972443a9ffba06ae8bb8b6f,
title = "Neuraminidase inhibitors for influenza: Fully evaluating benefits and harms",
author = "Andreas Handel and Ebell, {Mark H.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/S2213-2600(15)00066-1",
language = "English (US)",
volume = "3",
pages = "e7--e8",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Neuraminidase inhibitors for influenza

T2 - Fully evaluating benefits and harms

AU - Handel, Andreas

AU - Ebell, Mark H.

PY - 2015/3/1

Y1 - 2015/3/1

UR - http://www.scopus.com/inward/record.url?scp=84924292591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924292591&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(15)00066-1

DO - 10.1016/S2213-2600(15)00066-1

M3 - Article

VL - 3

SP - e7-e8

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 3

ER -